ARHGEF16 and colonic neoplasm: Furthermore, we found that Saracatinib treatment inhibited ARHGEF16-overexpressing HCT116 cell proliferation and migration compared with the cells in the absence of Saracatinib, indicating the inhibitory role of Saracatinib for ARHGEF16-induced colon cancer cell proliferation and migration (Fig. 6c, d), in line with the results of FYN knockdown.